CellWell record HH-133807
Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins
Julia Brandts; Marlo Verket; Alberto Zambon; Nikolaus Marx; Dirk Müller-Wieland; Massimo Federici
2026
In plain language
This review argues that non-HDL-cholesterol and apolipoprotein B better capture atherogenic risk than LDL-C alone and should guide more individualized lipid-lowering therapy in patients with diabetes.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-133807
Produced by the CellWell Research Engine, custom software owned and operated by CellWell. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.